Cargando…
Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245298/ https://www.ncbi.nlm.nih.gov/pubmed/34239792 http://dx.doi.org/10.7759/cureus.15360 |
_version_ | 1783716087717691392 |
---|---|
author | Abuserewa, Sherif T Duff, Richard Becker, Gregory |
author_facet | Abuserewa, Sherif T Duff, Richard Becker, Gregory |
author_sort | Abuserewa, Sherif T |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor. In this review of literature, we will be focusing on main lines of treatment including current medications, supportive care, lung transplantation evaluation, and potential future strategies of treatment. |
format | Online Article Text |
id | pubmed-8245298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-82452982021-07-07 Treatment of Idiopathic Pulmonary Fibrosis Abuserewa, Sherif T Duff, Richard Becker, Gregory Cureus Internal Medicine Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor. In this review of literature, we will be focusing on main lines of treatment including current medications, supportive care, lung transplantation evaluation, and potential future strategies of treatment. Cureus 2021-05-31 /pmc/articles/PMC8245298/ /pubmed/34239792 http://dx.doi.org/10.7759/cureus.15360 Text en Copyright © 2021, Abuserewa et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Abuserewa, Sherif T Duff, Richard Becker, Gregory Treatment of Idiopathic Pulmonary Fibrosis |
title | Treatment of Idiopathic Pulmonary Fibrosis |
title_full | Treatment of Idiopathic Pulmonary Fibrosis |
title_fullStr | Treatment of Idiopathic Pulmonary Fibrosis |
title_full_unstemmed | Treatment of Idiopathic Pulmonary Fibrosis |
title_short | Treatment of Idiopathic Pulmonary Fibrosis |
title_sort | treatment of idiopathic pulmonary fibrosis |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245298/ https://www.ncbi.nlm.nih.gov/pubmed/34239792 http://dx.doi.org/10.7759/cureus.15360 |
work_keys_str_mv | AT abuserewasherift treatmentofidiopathicpulmonaryfibrosis AT duffrichard treatmentofidiopathicpulmonaryfibrosis AT beckergregory treatmentofidiopathicpulmonaryfibrosis |